Life Science Start-Ups: Tech Transfer Deals, March 2014
• By Deanna Kamienski, Beth Allan, Andrea Mancini, Amanda Micklus, Maureen Riordan, and Theresa Surprenant
Derived from Strategic Transactions, a fully searchable premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced January through February 2014.
Abyrx receives option on Haibo’s soft tissue hemostat
Haibo Biotechnology Institute licensed biomaterials start-up Abyrx Inc. an option for exclusive worldwide development, manufacturing, and distribution rights (outside of China) to its plant-derived, resorbable soft tissue hemostat...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.
Private Company Edition: SV Health Investors revealed the final closing of its second Dementia Discovery Fund. Also, Eikon cut nearly 15% of its staff, Pathos AI raised $365m in series D venture capital and CellCentric completed a $120m series C round, among other financings.
